A Phase 2 Clinical Trial to Evaluate the Safety, Immunogenicity, and Clinical Benefit of a CMV Immunotherapeutic Vaccine in Donors and CMV-Seropositive Recipients Undergoing Allogeneic, Matched Hematopoietic Cell Transplant (HCT) [Vical Inc. Protocol CB01-202-00]

Trial Profile

A Phase 2 Clinical Trial to Evaluate the Safety, Immunogenicity, and Clinical Benefit of a CMV Immunotherapeutic Vaccine in Donors and CMV-Seropositive Recipients Undergoing Allogeneic, Matched Hematopoietic Cell Transplant (HCT) [Vical Inc. Protocol CB01-202-00]

Completed
Phase of Trial: Phase II

Latest Information Update: 26 Feb 2013

At a glance

  • Drugs VCL CB01 (Primary)
  • Indications Cytomegalic inclusion disorders; Cytomegalovirus infections
  • Focus Adverse reactions; Pharmacodynamics; Therapeutic Use
  • Most Recent Events

    • 26 Feb 2013 Additional lead trial centre identified as reported by ClinicalTrials.gov.
    • 12 Jan 2012 Results published in The Lancet Infectious Diseases journal, as reported in a Vical media release.
    • 14 Jul 2011 Results have been presented at DNA Vaccines 2011 according to a Vical media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top